tropical diseases prevalent in low-income settings. The growing gap between the need for new pharmaceuticals and their …-promoting pharmaceuticals. Over the past three decades, prior reforms based on using these levers to incentivize drug development have been … innovation has both benefits and substantial problems for public health, including negative consequences for the patients these …

Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation …, while simultaneously encouraging dynamic investments in innovation. As a result of this feature, the public provision of … at least $2.8 billion of annual value from extra innovation. These two components alone cover 87% of the social cost of …

Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation …, while simultaneously encouraging dynamic investments in innovation. As a result of this feature, the public provision of … at least $2.8 billion of annual value from extra innovation. These two components alone cover 87% of the social cost of …